GSK3B and Miyoshi myopathy: In MM cells, as expected, β-catenin protein levels were reduced by DFX treatment, accompanied by decreased levels of phosphorylated-GSK-3β (inactive form), resulting in the degradation of β-catenin (Figure 5A).